Spruce Street Capital
Latest statistics and disclosures from Spruce Street Capital's latest quarterly 13F-HR filing:
- Central Index Key (CIK): 0002050194
Tip: Access up to 7 years of quarterly data
Positions held by Spruce Street Capital consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Spruce Street Capital
Spruce Street Capital holds 30 positions in its portfolio as reported in the June 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals Intl Ord Shs Cl A (KNSA) | 11.5 | $59M | 918k | 63.95 |
|
|
| Relay Therapeutics (RLAY) | 11.0 | $56M | 3.0M | 18.71 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 8.8 | $45M | 1.4M | 32.45 |
|
|
| Relmada Therapeutics (RLMD) | 8.7 | $44M | 6.4M | 6.92 |
|
|
| Alto Neuroscience Com Shs (ANRO) | 7.0 | $36M | 1.4M | 26.39 |
|
|
| Dianthus Therapeutics (DNTH) | 6.8 | $35M | 355k | 97.48 |
|
|
| Alkermes SHS (ALKS) | 5.6 | $29M | 544k | 52.40 |
|
|
| Savara (SVRA) | 4.2 | $21M | 3.5M | 6.16 |
|
|
| Vaxcyte (PCVX) | 3.5 | $18M | 306k | 58.13 |
|
|
| Enliven Therapeutics (ELVN) | 3.3 | $17M | 329k | 50.75 |
|
|
| Enanta Pharmaceuticals (ENTA) | 3.1 | $16M | 1.1M | 14.58 |
|
|
| Perspective Therapeutics Com New (CATX) | 2.5 | $13M | 3.7M | 3.41 |
|
|
| Inflarx Nv (IFRX) | 2.4 | $12M | 5.4M | 2.24 |
|
|
| Surrozen Com New (SRZN) | 2.2 | $11M | 432k | 25.95 |
|
|
| Alumis (ALMS) | 2.2 | $11M | 393k | 28.14 |
|
|
| Century Therapeutics (IPSC) | 2.0 | $9.9M | 4.1M | 2.45 |
|
|
| Minerva Neurosciences Com New (NERV) | 1.8 | $9.2M | 1.7M | 5.55 |
|
|
| Sab Biotherapeutics Com New (SABS) | 1.7 | $8.6M | 2.2M | 3.90 |
|
|
| An2 Therapeutics (ANTX) | 1.6 | $8.0M | 1.7M | 4.84 |
|
|
| Erasca (ERAS) | 1.5 | $7.7M | 423k | 18.32 |
|
|
| Inhibikase Therapeutics Com New (IKT) | 1.4 | $7.3M | 3.6M | 2.03 |
|
|
| Research Alliance Corp Iii Ord Shs Cl A | 1.0 | $5.4M | 500k | 10.70 |
|
|
| Helix Acquisition Corp Iii Usd Cl A Ord Shs (HLXC) | 1.0 | $5.3M | 500k | 10.64 |
|
|
| Zai Lab Adr (ZLAB) | 1.0 | $5.3M | 279k | 19.00 |
|
|
| Achieve Life Sciences (ACHV) | 0.9 | $4.8M | 737k | 6.53 |
|
|
| Lexeo Therapeutics (LXEO) | 0.8 | $4.3M | 929k | 4.66 |
|
|
| Alector (ALEC) | 0.8 | $4.2M | 2.1M | 2.01 |
|
|
| Athira Pharma (LONA) | 0.7 | $3.6M | 394k | 9.19 |
|
|
| Corvus Pharmaceuticals (CRVS) | 0.7 | $3.5M | 232k | 14.94 |
|
|
| Jatt Ii Acquisition Corp Ord Shs | 0.4 | $1.8M | 160k | 11.36 |
|
Past Filings by Spruce Street Capital
SEC 13F filings are viewable for Spruce Street Capital going back to 2026
- Spruce Street Capital 2026 Q2 filed Aug. 13, 2026